In 2024, the FDA approved resmetirom (Rezdiffra) for adults with noncirrhotic NASH with F2F3 fibrosis, marking the first approved pharmacotherapy specifically for this condition
Available at Accessed 11/10/21
(It could be approved by late 2026.) Still, some guys like Johic are buying retatrutide at their own risk through a gray market of medical clinics and med spas, research peptide outlets (where drugs are sold for research purposes), compounding pharmacies, and e-commerce sites
Even a single month of GobyMeds compounded tirzepatide at $299 represents a fraction of those prices
5-Amino-1MQ is relatively affordable because it is taken orally, eliminating the need for bacteriostatic water and syringes
Your progress is tracked over time, giving you a clearer view of how your body is transforming